Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis

Kidney International

Volumn 88, Issue 3, 2015, Pages 515-527

  Li, Jianzhong ^a   Ren, Jiafa ^a   Liu, Xin ^a   Jiang, Lei ^a   He, Weichun ^a   Yuan, Weiping ^b   Yang, Junwei ^a   Dai, Chunsun ^a,c  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cell signaling; fibroblast; fibrosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; FIBRONECTIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; ACTIN; CARRIER PROTEIN; MULTIPROTEIN COMPLEX; RICTOR PROTEIN, MOUSE; RICTOR PROTEIN, RAT; SMOOTH MUSCLE ACTIN, RAT; TARGET OF RAPAMYCIN KINASE; TGFB1 PROTEIN, HUMAN; TOR COMPLEX 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CELL LINE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KIDNEY FIBROSIS; KIDNEY INTERSTITIUM CELL; KIDNEY PARENCHYMA; MACROPHAGE; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; NRK 49F CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; URETER OBSTRUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; FIBROBLAST; FIBROSIS; GENETIC TRANSFECTION; GENETICS; KIDNEY; KIDNEY DISEASES; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TIME FACTOR;

ACTINS; ANIMALS; CARRIER PROTEINS; CELL LINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; FIBRONECTINS; FIBROSIS; KIDNEY; KIDNEY DISEASES; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MULTIPROTEIN COMPLEXES; MYOFIBROBLASTS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1; URETERAL OBSTRUCTION;

EID: 84940789259     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.119     Document Type: Article

References (52)

1. Sharma SK, Zou H, Togtokh A, et al. Burden of CKD, proteinuria, and cardiovascular risk among Chinese, Mongolian, and Nepalese participants in the International Society of Nephrology screening programs. Am J Kidney Dis. 2010; 56: 915-927.
2. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011; 7: 684-696.
3. Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest. 2014; 124: 2299-2306.
4. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol. 2010; 6: 643-656.
5. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013; 493: 338-345.
6. Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 2011; 12: 295-303.
7. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009; 122: 3589-3594.
8. Inoki K. Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res Clin Pract. 2008; 82: S59-S62.
9. Mori H, Inoki K, Masutani K, et al. The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun. 2009; 384: 471-475.
10. Lieberthal W, Fuhro R, Andry C, et al. Rapamycin delays but does not prevent recovery from acute renal failure: role of acquired tubular resistance. Transplantation. 2006; 82: 17-22.
11. Lieberthal W, Fuhro R, Andry CC, et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol. 2001; 281: F693-F706.
12. Grahammer F, Haenisch N, Steinhardt F, et al. mTORC1 maintains renal tubular homeostasis and is essential in response to ischemic stress. Proc Natl Acad Sci USA. 2014; 111: E2817-E2826.
13. Jiang L, Xu L, Mao J, et al. Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. J Am Soc Nephrol. 2013; 24: 1114-1126.
14. Goc A, Choudhary M, Byzova TV, et al. TGFbeta- And bleomycin-induced extracellular matrix synthesis is mediated through Akt and mammalian target of rapamycin (mTOR). J Cell Physiol. 2011; 226: 3004-3013.
15. Cybulski N, Hall MN. TOR complex 2: a signaling pathway of its own. Trends Biochem Sci. 2009; 34: 620-627.
16. Goncharova EA, Goncharov DA, Li H, et al. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol. 2011; 31: 2484-2498.
17. Kocalis HE, Hagan SL, George L, et al. Rictor/mTORC2 facilitates central regulation of energy and glucose homeostasis. Mol Metab. 2014; 3: 394-407.
18. Facchinetti V, Ouyang W, Wei H, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008; 27: 1932-1943.
19. Gu Y, Lindner J, Kumar A, et al. Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. Diabetes. 2011; 60: 827-837.
20. Li J, Xu Z, Jiang L, et al. Rictor/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury. Kidney Int. 2014; 86: 86-102.
21. Lamouille S, Connolly E, Smyth JW, et al. TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci. 2012; 125: 1259-1273.
22. Chang W, Wei K, Ho L, et al. A critical role for the mTORC2 pathway in lung fibrosis. PLoS One. 2014; 9: e106155.
23. Tschopp O, Yang ZZ, Brodbeck D, et al. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development. 2005; 132: 2943-2954.
24. Kim EK, Yun SJ, Ha JM, et al. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis. Oncogene. 2011; 30: 2954-2963.
25. Canaud G, Bienaime F, Viau A, et al. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med. 2013; 19: 1288-1296.
26. Yang J, Dai C, Liu Y. Hepatocyte growth factor suppresses renal interstitial myofibroblast activation and intercepts Smad signal transduction. Am J Pathol. 2003; 163: 621-632.
27. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol. 1996; 7: 2495-2508.
28. Humphreys BD, Lin SL, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010; 176: 85-97.
29. LeBleu VS, Taduri G, O'Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013; 19: 1047-1053.
30. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010; 21: 212-222.
31. Wada T, Sakai N, Matsushima K, et al. Fibrocytes: a new insight into kidney fibrosis. Kidney Int. 2007; 72: 269-273.
32. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008; 214: 199-210.
33. Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/ M mediates kidney fibrosis after injury. Nat Med. 2010; 16: 535-543.
34. Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emerge via endothelial-To-mesenchymal transition. J Am Soc Nephrol. 2008; 19: 2282-2287.
35. Zeisberg M, Bonner G, Maeshima Y, et al. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol. 2001; 159: 1313-1321.
36. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 2010; 21: 1819-1834.
37. Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011; 121: 2197-2209.
38. Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011; 332: 1317-1322.
39. Yu Y, Yoon SO, Poulogiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011; 332: 1322-1326.
40. Liu P, Gan W, Inuzuka H, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol. 2013; 15: 1340-1350.
41. Humphrey SJ, Yang G, Yang P, et al. Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. Cell Metab. 2013; 17: 1009-1020.
42. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999; 96: 857-868.
43. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307: 1098-1101.
44. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol. 2009; 5: 319-328.
45. Rodriguez-Pena AB, Grande MT, Eleno N, et al. Activation of Erk1/2 and Akt following unilateral ureteral obstruction. Kidney Int. 2008; 74: 196-209.
46. Lan A, Du J. Potential role of Akt signaling in chronic kidney disease. Nephrol Dial Transplant. 2014; 30: 385-394.
47. Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005; 280: 40406-40416.
48. Artunc F, Lang F. Mineralocorticoid and SGK1-sensitive inflammation and tissue fibrosis. Nephron Physiol. 2014; 128: 35-39.
49. Zhou Y, Xiong M, Niu J, et al. Secreted fibroblast-derived miR-34a induces tubular cell apoptosis in fibrotic kidney. J Cell Sci. 2014; 127: 4494-4506.
50. Anders HJ, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 2011; 80: 915-925.
51. Grande MT, Perez-Barriocanal F, Lopez-Novoa JM. Role of inflammation in tubulo-interstitial damage associated to obstructive nephropathy. J Inflamm (Lond) 2010; 7: 19.
52. Lopez-De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem. 1985; 33: 737-743.